As the rise of next-generation sequencing has driven demand for new analytical tools, many software companies that have long served array users have shifted their resources to this rapidly growing segment of the market.

But microarray users haven't been left behind as a result of this trend, according to sources familiar with the industry who told BioArray News that these new NGS analysis tools will have a "trickle-down effect" or "fringe benefit" for array clients.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.